Heide Anderson

Heide Anderson serves as a key procurement lead within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate the development of medical countermeasures against infectious, immunologic, and allergic threats. She manages high-stakes acquisitions for biological product manufacturing, ensuring timely procurement of critical research inputs such as vaccines, therapeutics, and biological reagents essential for high-containment laboratories. Her work directly enables NIAID’s response to emerging public health emergencies by securing scalable, GMP-compliant manufacturing capabilities and advanced biosafety infrastructure. Anderson’s acquisitions are strategically aligned with national preparedness goals, emphasizing rapid deployment and regulatory compliance. Her primary contractor relationships center on Quality Biological, Inc., a leading provider of biological reference materials and pathogen-derived products, and Genomic Labs Ltd., a specialized supplier of genomic reagents and diagnostic development tools. These partnerships reflect a focus on trusted, mission-critical vendors with proven expertise in biosafety level 3 and 4 (BSL-3/4) compliant manufacturing. Anderson’s contracting approach prioritizes technical reliability and supply chain resilience over volume, fostering long-term collaborations with niche manufacturers capable of meeting stringent federal biospecimen and biocontainment standards. Anderson’s procurement portfolio reflects no set-aside preferences, with 100% of awards issued under full and open competition. This indicates a deliberate emphasis on technical capability and regulatory readiness over socioeconomic categorization, aligning with NIAID’s urgent need for specialized biological manufacturing capacity. While small business participation is not formally prioritized, her contracts may still include small firms when they demonstrate unique technical qualifications essential to mission success. Her industry focus is exclusively on NAICS 325414 — Biological Product (except Diagnostic) Manufacturing — encompassing the procurement of live attenuated vaccines, monoclonal antibodies, viral vectors, and other biologics for preclinical and clinical development. Anderson’s expertise lies in navigating complex regulatory pathways, ensuring procurements meet FDA and CDC standards, and supporting the transition of laboratory-scale innovations into scalable, GMP-compliant production systems.